Drug Trial Radar · NCT00847626
Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
Last checked: Nov 19, 2026Latest source record: Feb 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,711
Actual
Start
Jan 2009
Primary completion
May 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.
Conditions
- Hypertension
Interventions
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
ChlorthalidoneDrug
Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
ChlorthalidoneDrug
Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomilDrug
Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomilDrug
Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomilDrug
Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)Time frame: Baseline and Week 8.
- Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)Time frame: Baseline and Week 8.
Locations
99 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Columbiana, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Chandler, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Buena Park, California
Site not named
Carmichael, California
Site not named
Costa Mesa, California
Site not named
Irvine, California
Site not named
Palm Springs, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Vista, California
Site not named
Walnut Creek, California
Site not named
Middletown, Delaware
Site not named
Bradenton, Florida
Site not named
Deerfield Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Hallandale, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Longwood, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Ormond Beach, Florida
Site not named
St. Petersburg, Florida
Site not named
Atlanta, Georgia
Site not named
Buffalo Grove, Illinois
Site not named
Libertyville, Illinois
Site not named
Melrose Park, Illinois
Site not named
Fishers, Indiana
Site not named
Indianapolis, Indiana
Site not named
Erlanger, Kentucky
Site not named
Madisonville, Kentucky
Site not named
Paducah, Kentucky
Site not named
Rockville, Maryland
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.